Printer Friendly

Expression of soluble adenylyl cyclase in lentigo maligna: use of immunohistochemistry with anti-soluble adenylyl cyclase antibody (R21) in diagnosis of lentigo maligna and assessment of margins.

Soluble adenylyl cyclase (sAC) is a novel class of adenylyl cyclase, the enzyme responsible for generation of cyclic adenosine monophosphate. Cyclic adenosine monophosphate is a key intracellular signaling molecule involved in regulation of melanocyte differentiation, proliferation, and melanogenesis. Soluble adenylyl cyclase is ubiquitously expressed in many tissues. (1-3) Soluble adenylyl cyclase is localized in different subcellular microdomains (cytoplasm, Golgi area, nucleus) in different tissues. Soluble adenylyl cyclase responds to both extracellular (tumor necrosis factor, netrin, nerve growth factor) and intracellular (bicarbonate, pH, calcium) signals. (2,4-12)

Magro et al (13) have recently reported expression of sAC in benign melanocytic proliferations and melanomas using a monoclonal antibody against sAC designated R21. This paper demonstrated that sAC expression in benign nevi is enriched to the perinuclear Golgi region. In contrast, many melanomas show apparent relocation of sAC to the nucleus, frequently accompanied by loss of the perinuclear Golgi staining pattern. In addition, different histologic subsets of melanoma show distinct predominant patterns and intensity of staining with R21. The most striking reproducible pattern is strong pan-nuclear expression of sAC in lentigo maligna melanoma along with other melanomas exhibiting a lentiginous radial growth phase (ie, acral lentiginous and mucosal lentiginous melanomas). Pan-nuclear staining is also observed in a subset of neoplastic cells in superficial spreading melanomas and nodular melanomas, but not to the extent seen in the setting of lentiginous melanomas. These results suggest that, in contrast to the currently available first-generation melanocytic markers such as S100, microphthalmia transcription factor (MITF), and Martl/Melan A, (14-18) R21 immunohistochemistry can be used to distinguish melanoma from benign melanocytic proliferations and may be useful in the subclassification of melanoma.

In this report we share our experience with the use of the R21 antibody as a diagnostic adjunct both in the initial evaluation of lentigo maligna and in the assessment of margins.

MATERIALS AND METHODS

Two sets of cases and 2 staining protocols were examined. The initial set of cases was represented by 31 lentigo maligna re-excision specimens that C.M.M. prospectively encountered in her routine clinical practice at the Weill Medical College of Cornell University (New York, New York) during a period of 6 months. In each case, hematoxylin-eosin-stained sections, deeper sections through relevant tissue blocks, and sAC immunohistochemical antibody stains were conducted. In certain cases a Melan A stain was also conducted on selected blocks. The details of the sAC analysis will be given below. The methodology for the stain has been previously published. (3) Ten control cases were examined, comprising re-excision specimens for nonmelanoma skin cancer associated with extensive chronic photoactivation of melanocytes.

In parallel studies performed in Boston, A.Z. independently examined 41 cases of classic lentigo maligna and 38 cases of reactive lentiginous melanocytic hyperplasia incidentally found on excision and/or biopsy specimens of nonmelanoma skin cancer during the period of July 1 to October 15, 2011 (see below). Using the same antibody, A.Z. established a distinct staining protocol designed to highlight only melanocyte pan-nuclear staining while eliminating all background staining. To validate the modified protocol, 44 benign nevi and 30 non-lentigo maligna melanomas were also examined.

All 4 authors reviewed both sets of data to establish a consensus regarding staining results using both protocols.

R21 Immunohistochemistry

R21 is a mouse monoclonal antibody directed against amino acids 203-216 of human sAC protein. (3) Application of R21 immunohistochemistry for evaluation of sAC expression in melanocytic proliferations was recently described in great detail by Magro et al. (13) In this study, results were obtained as previously described (13) or using a modified protocol with a higher dilution of R21 antibody (1:1200-2000). The modified protocol takes advantage of the high level of sAC expression in lentigo maligna and achieves conditions that preserve the pan-nuclear staining in lentigo maligna but minimize staining in benign melanocytes and other cell types. This allows for a focused evaluation of sAC nuclear staining. R21 staining was performed using Leica, (Leica Microsystems, Buffalo Grove, Illinois), DAKO (Carpinteria, California), or Ventana (Tucson, Arizona) automatic stainers.

Assessment of sAC Staining

Using conditions described in our previous paper, (13) the main staining pattern that defined chronic photoactivation of melanocytes is one of discrete dotlike Golgi staining, often accompanied by nucleolar staining. In contrast, in lentigo maligna, a striking pattern of pan-nuclear staining highlighting melanocytes typically larger than the adjacent keratinocyte nucleus is characteristic. In each case, the number of cells exhibiting a pan-nuclear staining pattern within one high-power field (X40) of the inked margin was determined. Melanocytes that either did not stain or showed other staining patterns (ie, Golgi and incomplete granular nuclear staining) were not deemed as positive cells. A similar count was given for Melan A-positive-staining melanocytes. In cases where both stains were done, a pan-nuclear sAC to Melan A ratio was determined.

Using the modified technique developed by A.Z., the antibody was applied at a dilution designed to highlight only pan-nuclear staining. A lesion was considered positive if at least 50% of evaluable melanocytes in at least one X 20 magnification field showed unequivocal nuclear staining. Most cases showed uniform staining throughout the entire lesion. In some cases areas of both positive and negative staining were observed. Resting melanocytes present in sections were also scrutinized for R21 staining.

Other Methods

As part of routine workup some lesions were also stained with S100, Mart1/Melan A, or MITF antibodies according to routine laboratory procedures.

Statistical Methods

Descriptive statistics included estimations such as mean, standard deviation, and medians. Chi-square statistics (ie, Fisher exact test) were used, where appropriate, as tests of association and the weighted kappa statistics provided us with diagnostic agreement. Significance level was set at [alpha] = .05.

RESULTS

Utility of sAC in the Evaluation of Lentigo Maligna Margins

Using the previously published protocol, we examined a total of 31 excision specimens to determine the presence of residual lentigo maligna and investigate adequacy of excision. In 27 of the 31 cases, there was evidence of residual lentigo maligna, whereas in 4 of the cases a residual atypical intraepidermal melanocytic proliferation was identified although not diagnostic of fully evolved lentigo maligna. In 17 of 31 cases associated with a positive margin, the mean number of pan-nuclear-staining melanocytes within one high-power field at the margin was 15.88 (SD = 6.77; median, 13.0). The average pan-nuclear sAC to Melan A ratio at the margin was 0.72 (SD = 0.24; median, 0.725). A representative case with positive margin is illustrated in Figure 1, A and B. When the margin was negative (n = 14), there was an average of 2.24 pan-nuclear-staining melanocytes within one high-power field (median, 2.0; SD = 2.80; Figure 2, A and B). The pan-nuclear sAC to Melan A ratio at the margin was 0.22 (median, 0.155; SD = 0.304). Thus, more than 9 pan-nuclear-staining melanocytes within one high-power field and/or an sAC to Melan A ratio greater than 0.5 was associated with a positive margin. Five or less pan-nuclear-staining melanocytes and/or an sAC to Melan A ratio less than 0.3 was associated with a negative margin (P < .001; weighted [kappa] = 0.625). This value of k indicates substantial agreement with margin results. All nonmelanoma skin cancer re-excision specimens showed a benign pattern of sAC staining, as revealed by a dotlike Golgi staining pattern with variable nucleolar staining. The overall density within one high-power field of the lateral margin ranged from 0 to 4 cells per high-power field. The sAC/Melan A ratio was less than 0.1. These findings are consistent with the notion that nuclear staining with R21 is specific for melanocytes representing lentigo maligna, whereas Melan A stains both lentigo maligna and normal melanocytes.

Assessment of sAC Using the Modified Stringent Protocol

Following our initial assessment of lentigo maligna margins with R21 and Melan A, we felt this immunostain held promise as a tool to both diagnose lentigo maligna and assess surgical margins. However, because of the occasional keratinocyte staining of this ubiquitous protein, we wanted to establish whether a more stringent immunostaining protocol could allow for a focused evaluation of nuclear sAC staining exclusively in melanocytes. Our hope was that such a protocol would allow for a more simplified evaluation of melanoma. Results of staining using this protocol are summarized in the Table. Indeed, using a modified protocol with 50% less antibody, nuclear expression of sAC was observed in 87.8% of lentigo malignas. Figure 3, A through D, illustrates a representative case showing strong nuclear staining with R21 of both in situ and invasive lentigo maligna melanoma. Focal areas with negative R21 staining were observed in 2 of 35 R21-positive cases. Figure 4, A and B, shows the peripheral margin of a representative resection of lentigo maligna melanoma. It demonstrates that the R21 stain allows precise determination of the limit of peripheral spread of lentigo maligna.

[FIGURE 1 OMITTED]

Various benign melanocytic nevi were examined, including dermal, compound, junctional, dysplastic, and Spitz nevi (Table). All cases, except for 1, were devoid of all R21 nuclear staining (Figure 5, A through C). The 1 case in which nuclear expression was observed was reported as a junctional dysplastic nevus (data not shown).

Most lesions diagnosed as lentiginous junctional hyperplasias showed no nuclear staining with R21 (Figure 6, A through D; Table); 28.9% of lesions were positive (Figure 7, A through C). R21 staining in lentigo maligna versus melanocytic hyperplasia was statistically significant by Fisher exact test (P < .001). R21-positive melanocytic hyperplasias were scrutinized for presence of atypical melanocytes. Occasional enlarged or hyperchromatic melanocytes could be identified in 6 of 11 lesions. However, no atypical features were observed in 5 of 11 R21-positive melanocytic hyperplasias. In these cases all the melanocytes were small and inconspicuous in routine sections.

[FIGURE 2 OMITTED]

We also examined 30 non-lentigo maligna melanomas using the stringent protocol. As expected, we confirmed the findings of Magro et al, (13) and found nuclear expression of sAC in 40% of non-lentigo maligna melanomas.

COMMENT

Lentigo maligna is one of the most common forms of malignant melanoma. Recent insights into the molecular pathogenesis of melanoma revealed that melanomas occurring on the sun-exposed skin show a distinct pattern of chromosomal instability and are less frequently associated with BRAF mutations, which preferentially occur in melanomas occurring on intermittently sun-exposed skin. (19,20) Despite these advancements in the molecular understanding of lentigo maligna, the histologic diagnosis of lentigo maligna remains problematic. The classic morphologic depiction of incipient lentigo maligna is one characterized by single cell lentiginous proliferation at the dermoepidermal junction of atypical melanocytes manifesting large angulated hyperchromatic nuclei with an irregular pattern of melanization. With progression of the in situ lesion, pagetoid spread and prominent junctional nest formation occurs. It is well known that benign reactive melanocytic hyperplasias in sun-exposed areas or in the vicinity of surgical scars can exhibit histologic patterns similar to early lentigo maligna. In particular, the classic morphologic depiction of chronic photoactivation of melanocytes includes lentiginous (single cell) melanocytic proliferation with cellular enlargement, the potential for nuclear hyperchromasia, binucleation and multinucleation, and low-level pagetoid ascent.

In this regard, developing an antibody that reliably distinguishes between chronic photoactivation, paracicatricial melanocytic hyperplasia, junctional nevus, and lentigo maligna would be a valuable diagnostic adjunct. The first-generation melanocytic markers, such as S100, MITF, and Mart1/Melan A, do not distinguish between benign and malignant melanocytes. The most common adjunctive immunohistochemical stain in the evaluation of lentigo maligna margins is Mart 1/Melan A. (21) However, in our experience we find its sensitivity in highlighting benign melanocytes in zones of chronic photoactivation renders the stain suboptimal in the accurate assessment of lentigo maligna margins. In our study, a relatively high-density pattern of proliferation revealed by Melan A stain could be seen at seemingly negative margins. Excessive pagetoid ascent and/or junctional nest formation along the dermal-epidermal junction could be deemed a pattern indicative of residual lentigo maligna in some cases. However, our experience confirmed by a recent study suggests that these features can be observed on Melan A stains procured from normal skin chronically exposed to sun. (22) In the same study, the Mart 1/Melan A stained section showed stacking of melanocytes, confluence of melanocytes, or suprabasilar spread and adnexal extension in more than 95% of cases. Almost 20% of negative control specimens showed at least 4 of the criteria held to be suspicious for lentigo maligna, defining a pattern closely mimicking lentigo maligna/lentigo maligna melanoma, and up to 33% of normal skin samples could show at least one suspicious feature. (22) In another study, melanocyte confluence was observed in as much as 45% of Melan A-stained excisions of basal cell carcinoma on sun-exposed skin, and cytologic atypia and pagetoid spread were seen in 19% and 3% of cases, respectively. (23)

We have presented our experience with the use of antisAC antibodies (R21) in the evaluation of lentigo maligna, including the use of this stain to evaluate margins. We provide evidence that R21 is a second-generation immunohistochemical marker. It is the first stain to our knowledge that can discriminate between benign and malignant melanocytic proliferations.

In lentigo maligna, we observed a strong pan-nuclear staining of atypical enlarged junctional and pagetoid melanocytes. With invasion, one can see a similar pattern of pan-nuclear staining. In most cases, regardless of the protocol used one can easily determine the margins of the lesion, often to the level of a single cell, by direct observation. In lesions stained by the original protocol, which also highlights sAC expression in keratinocytes, examination of margins can be facilitated by comparison between Melan A and R21 stains. If one examines the number of pan-nuclear-staining melanocytes within one high-power field of an inked margin, histologically positive margins are associated with a number of positive staining cells typically in excess of 9 and/or an sAC/ Melan A ratio approximating 1, whereas negative margins consistently give results of fewer than 5 cells manifesting the pan-nuclear staining pattern and/or a sAC/Melan A ratio approaching 0. These findings are consistent with our assertion that R21 nuclear expression provides greater specificity than Melan A for the distinction of the melanocytes that comprise lentigo maligna. Melan-A appears to highlight both lentigo maligna cells and the background melanocytes, whereas R21 highlights only the lentigo maligna. This is consistent with our finding that sAC expression in nevi and amid chronically photoactivated melanocytes is almost exclusively restricted to the Golgi area and nucleoli. (13)

We optimized the R21 staining protocol by titrating the antibody to minimize staining of resting melanocytes, keratinocytes, cutaneous adnexa, and inflammatory cells. Using this modified technique, the interpretation of a positive result depends exclusively on the presence or absence of pan-nuclear staining. Our results with the modified protocol estimate sensitivity of R21 staining in lentigo maligna at 87.8%. The R21 stain can precisely determine the extent of involvement by lentigo maligna, in some cases up to the level of a single cell. False-negative cases were otherwise histologically and clinically classic lentigo maligna lesions that did not express sufficient levels of sAC to be detected by R21 in our more stringent protocol.

Further studies are needed to better understand why some "benign" melanocytes exhibit a pan-nuclear pattern of sAC expression. Do these melanocytes contain genetic aberrations? Do they represent transitional lesions between frank benignity and cancer? We hope that ongoing basic research into the biology of sAC will offer explanations. An important parallel is drawn with the common V600E BRAF mutations driving melanoma but also commonly present in benign nevi.

[FIGURE 3 OMITTED]

[FIGURE 4 OMITTED]

[FIGURE 5 OMITTED]

Regardless of the antibody dilution used, authors had qualitatively similar results to published reports. (13) Pathologists who are interested in examining both pan-nuclear and Golgi staining, as C.M.M. does in routine practice, will prefer a more concentrated dilution of the antibody, whereas those who prefer to focus exclusively on the pannuclear staining pattern will prefer a more diluted stain.

[FIGURE 6 OMITTED]

[FIGURE 7 OMITTED]

In summary, unequivocal cases of lentigo maligna are defined by pan-nuclear expression of sAC amid the dominant intraepidermal melanocyte population; conversely, rare cells with pan-nuclear staining are likely not significant, especially if the cell is not enlarged (ie, morphologically abnormal). That said, one must always correlate R21 staining with routine morphologic assessment. As with any ancillary technique, a diagnostic interpretation based purely on immunohistochemical studies is not advised. The sAC immunostain, especially when coupled with Melan A (or MITF) to define a sAC/ Melan A (or sAC/MITF) ratio, is a very simple but discriminatory diagnostic test that allows a quick and reliable assessment of lentigo maligna margins. The exact titration of sAC needed to achieve optimal results will likely vary depending on the goal of the pathologist and immunostaining protocols of the laboratory.

The authors would like to acknowledge the excellent contributions of Mrs Anital King (Harvard Vanguard Medical Associates, Boston, Massachusetts), Mr Mohammad El-Hajahmad (Lahey Clinic, Burlington, MA), and Paul Chadwick (Weill Cornell Medical Center, New York, New York) during the optimization and validation of R21 staining. Lonny R. Levin, PhD, and Jochen Buck, MD, PhD (Weill Cornell Medical Center), provided the R21 antibody from CEP Biotech, Inc. Mary Cheang performed the statistical analysis. The technical staffing and slide preparations were paid for by dermatopathology research funds from the Department of Dermatology (Dr Magro). Dr Zippin is funded by the following: Clinique Clinical Scholars and 1 K08 CA 160657-01 (NCI).

References

(1.) Park HY, Gilchrest BA. Signaling pathways mediating melanogenesis [review]. Cell Mol Biol (Noisy-le-grand). 1999; 45(7):919-930.

(2.) Tresguerres M, Levin LR, Buck J. Intracellular cAMP signaling by soluble adenylyl cyclase. Kidney Int. 2011; 79(12):1277-1288.

(3.) Zippin JH, Chadwick PA, Levin LR, Buck J, Magro CM. Soluble adenylyl cyclase defines a nuclear cAMP microdomain in keratinocyte hyperproliferative skin diseases. J Invest Dermatol. 2010;130(5):1279-1287.

(4.) Cooper DM, Mons N, Karpen JW. Adenylyl cyclases and the interaction between calcium and cAMP signalling. Nature. 1995;374(6521):421-424.

(5.) Bundey RA, Insel PA. Discrete intracellular signaling domains of soluble adenylyl cyclase: camps of cAMP? Sci STKE. 2004; 2004(231):e19.

(6.) Feng QP, Zuo J, Meng Y, Fang FD. Nuclear localization region in soluble adenylyl cyclase [in Chinese]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2005; 27(3):280-284.

(7.) Feng Q, Zhang Y, Li Y, Liu Z, Zuo J, Fang F. Two domains are critical for the nuclear localization of soluble adenylyl cyclase. Biochimie. 2006; 88(3-4):319 328.

(8.) Krupinski J. The adenylyl cyclase family. Mol Cell Biochem. 1991; 104(1-2): 73-79.

(9.) Stessin AM, Zippin JH, Kamenetsky M, Hess KC, Buck J, Levin LR. Soluble adenylyl cyclase mediates nerve growth factor-induced activation of Rap1. J Biol Chem. 2006; 281(25): 17253-17258.

(10.) Hess KC, Jones BH, Marquez B, et al. The "soluble" adenylyl cyclase in sperm mediates multiple signaling events required for fertilization. Dev Cell. 2005; 9(2): 249-259.

(11.) Zippin JH, Chen Y, Nahirney P. et al. Compartmentalization of bicarbonate-sensitive adenylyl cyclase in distinct signaling microdomains. FASEB J. 2003; 17(1): 82-84.

(12.) Zippin JH, Farrell J, Huron D, et al. Bicarbonate-responsive "soluble" adenylyl cyclase defines a nuclear cAMP microdomain. J Cell Biol. 2004; 164(4): 527-534.

(13.) Magro CM, Crowson AN, Desmaze C, Zippin JH. Soluble adenylyl cyclase antibody profile as a diagnostic adjunct in the assessment of pigmented lesions. Arch Dermatol. 2012; 148(3):335-344. doi: 10.1001/archdermatol.2011.338.

(14.) Busam KJ, Chen YT, Old LJ, et al. Expression of Melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol. 1998; 22(8):976-982.

(15.) King R, Googe PB, Weilbaecher KN, Mihm MCJ, Fisher DE. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. Am J Surg Pathol. 2001; 25(1):51-57.

(16.) King R, Weilbaecher KN, McGill G, et al. Microphthalmia transcription factor: a sensitive and specific melanocyte marker for melanoma diagnosis. Am J Pathol 1999; 155(3):731-738.

(17.) Prieto VG, Shea CR. Immunohistochemistry of melanocytic proliferations. Arch Pathol Lab Med. 2011; 135(7):853-859.

(18.) Black WH, Thareja SK, Blake BP, Chen R, Cherpelis BS, Glass LF. Distinction of melanoma in situ from solar lentigo on sun-damaged skin using morphometrics and MITF immunohistochemistry. Am J Dermatopathol. 2011; 33(6):573-578.

(19.) Bastian BC, Olshen AB, LeBoit PE, et al. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol. 2003; 163(5):1765-1770.

(20.) Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005; 353(20):2135-2147.

(21.) Kelley LC, Starkus L. Immunohistochemical staining of lentigo maligna during Mohs micrographic surgery using MART-1. J Am Acad Dermatol. 2002; 46(1):78-84.

(22.) Bowen AR, Thacker BN, Goldgar DE, Bowen GM. Immunohistochemical staining with Melan-A of uninvolved sun-damaged skin shows features characteristic of lentigo maligna. Dermatol Surg. 2011; 37(5):657-663.

(23.) Hendi A, Wada DA, Jacobs MA, et al. Melanocytes in nonlesional sun-exposed skin: A multicenter comparative study. J Am Acad Dermatol. 2011; 65(6): 1186-1193.

Cynthia M. Magro, MD; Sung-Eun Yang, MD; Jonathan H. Zippin, MD, PhD; Artur Zembowicz, MD, PhD

Accepted for publication January 31, 2012

Published as an Early Online Release July, 24, 2012.

From the Departments of Pathology (Dr Magro) and Dermatology (Dr Zippin), Weill Medical College of Cornell University, New York, New York;the Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, Massachusetts (Dr Yang); and www.DermatopathologyConsultations.com, Boston, Massachusetts, the Department of Pathology, Lahey Clinic, Burlington, Massachusetts, and the Department of Pathology, Harvard Vanguard Medical Associates, Boston, Massachusetts (Dr Zembowicz).

Drs Zippin and Magro are cofounders of CEP Biotech, which holds the exclusive license to market the anti-sAC monoclonal antibodies developed at Weill Cornell Medical College, and are inventors on a patent that describes the use of sAC antibodies for the diagnosis of melanocytic proliferations. The other authors have no relevant financial interest in the products or companies described in this article.

Reprints: Artur Zembowicz, MD, PhD, Department of Pathology, www.DermatopathologyConsultations.com, 133 Brookline Ave, 6th Floor, Boston, MA 02215 (e-mail: dr.z@DermatopathologyConsultations.com).
Expression of Soluble Adenylyl Cyclase Staining
in Melanomas, Melanocytic Hyperplasias, and Nevi

 No. No. % Positive
Melanomas
 Lentigo maligna 41 36 87.8
 Other melanomas
 Total 30 12 40.0
 Melanoma in situ 2 2 100
 Superficial spreading 17 6 35.3
 Unclassified 9 3 33.3
 Acral lentiginous 1 0 0
 Mucosal lentiginous 1 1 100

Lentigo/melanocytic hyperplasia
 Total 38 11 28.9
 With atypia 23 6 26.1
 Without atypia 15 5 33.3

Nevi
 Total 44 1 2.3
 Compound 3 0 0
 Dermal 6 0 0
 Lentiginous junctional 8 0 0
 Lentiginous junctional with 12 1 0
 atypia
 Lentiginous compound 80 0
 dysplastic
 Spitz 7 0 0
COPYRIGHT 2012 College of American Pathologists
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Magro, Cynthia M.; Yang, Sung-Eun; Zippin, Jonathan H.; Zembowicz, Artur
Publication:Archives of Pathology & Laboratory Medicine
Date:Dec 1, 2012
Words:3793
Previous Article:Screening test results associated with cancer diagnoses in 287 women with cervical squamous cell carcinoma.
Next Article:Value-added benefits and utilization of pathologists' assistants.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters